Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995396 | 1.00 | LMNA (0.36) | LMNAPIK3CAFFAR4KDM4EMAPK1 | |
| SCHEMBL6835805 | 0.72 | LMNA (0.47) | LMNAKDM4EMAPK1NPSR1L3MBTL1 | |
| Bromide SCHEMBL6841110 | 0.71 | LMNA (0.46) | LMNAKDM4ECCNT1CCNA2CDK2 | |
| SCHEMBL15623071 | 0.66 | LMNA (0.43) | LMNAPIK3CAKDM4EMAPK1NPSR1 | |
| SCHEMBL26840411 | 0.64 | KDM4E (0.53) | LMNAKDM4EMAPK1NPSR1L3MBTL1 | |
| SCHEMBL28146832 | 0.60 | LMNA (0.47) | LMNAPIK3CAKDM4EMAPK1NPSR1 | |
| SCHEMBL31093398 | 0.59 | LMNA (0.48) | LMNAPIK3CAKDM4EMAPK1NPSR1 | |
| SCHEMBL26643728 | 0.59 | LMNA (0.44) | LMNAPIK3CAKDM4EMAPK1NPSR1 | |
| SCHEMBL309322 | 0.59 | LMNA (0.39) | LMNAKDM4EMAPK1NPSR1L3MBTL1 | |
| SCHEMBL5361682 | 0.59 | KDM4E (0.55) | LMNAKDM4EMAPK1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | LMNA 1598/4885PIK3CA 2087/4885FFAR4 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.